| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cfb19d2c57ea3524c4be27d297ea15b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c10ac713fadc8d725c86a7fd91214fb7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-525 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6863 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 |
| filingDate |
2008-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92e5a34893428d5c8809042f7691beb3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cbdb8f0113384966cedabcb1069ea83
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62a5ac418b212e3c8c8d43d209eb5f1b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d688634f11b4ce6f93506c4313564286
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f8c148fbb94acb73b9d0894e449fe93
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50b8c26882a0672bcfc0204ab459dcd8 |
| publicationDate |
2010-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2156189-A1 |
| titleOfInvention |
Tnf gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins |
| abstract |
TNFα gene expression can be used as a biomarker of a cell's sensitivity to antagonists of inhibitor of apoptosis proteins (IAPs). Methods of the invention are useful for screening patients to identify those who could benefit from administration of an IAP antagonist to treat various malignant or benign tumors, benign proliferative diseases, or autoimmune diseases. |
| priorityDate |
2007-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |